One-year Outcomes of Fixed-Dosing Aflibercept Therapy for pre treated and naive polypoidal choroidal vasculopathy patient
Authors:
Preprint
- 5 November 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. Methods: This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first three months (the loading phase), and thereafter, once every two months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months. Results: After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (pConclusions: The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients.Keywords
All Related Versions
This publication has 8 references indexed in Scilit:
- Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patientsClinical Ophthalmology, 2018
- Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2015
- Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese PatientsAmerican Journal of Ophthalmology, 2007
- Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek populationEye, 2004
- POLYPOIDAL CHOROIDAL VASCULOPATHY IN ITALYRetina, 2001
- Polypoidal choroidal vasculopathy in CaucasiansGraefe's Archive for Clinical and Experimental Ophthalmology, 2000